| Document Date: 2015-05-20 08:10:58
Open Document File Size: 18,33 KBShare Result on Facebook
City DUBLIN / BOSTON / / Company Medtronic plc / Tachycardia / / Continent Europe / / Country United States / Ireland / / Currency USD / / Facility Science University / Vanderbilt University Medical Center / / IndustryTerm treatment of cardiovascular disease / healthcare consumers / implantable cardiac device / medical technology alleviating pain / cardiac implantable electronic device / control / medical technology / / MedicalCondition surgical-site infections / congestive heart failure / CIED site infections / delayed infection / CIED Infections CIED infections / CIED infections / implant-related cardiac device site infections / cardiac device-related infection / cardiac arrhythmias / cardiovascular disease / diabetes / surgical site infection / only one reported infection / pain / CIED-related infection / endocarditis / Tachycardia / CIED infection / infection / renal failure / cardiac device site infections / infections / / MedicalTreatment incision / cardiac resynchronization therapy / surgical treatment / / Organization Heart Rhythm Society / FDA / Vanderbilt University Medical Center / Oregon Health & Science University in Portland / / Person Christopher R. Ellis / Charles A. Henrikson / Marshall Stanton / / Position principal investigator / vice president and general manager / study and assistant professor of medicine / Major / chief / / Product rifampin / / URL www.medtronic.com / /
SocialTag |
Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months May 15, :30 PM CT Long-term Citadel/Centurion Clinical Trial Findings and Independent Data Presented at Heart Rhythm So